MNKD Stock Analysis: Buy, Sell, or Hold?
MNKD - Mannkind Corporation
$6.01
0.22 (3.89%)
▲
5d:
+7.62%
30d:
+5.91%
90d:
+8.2%
BUY
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Feb 25, 2026
22d
Get Alerted When MNKD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
5 traders called MNKD this week
38% bullish • 5 bearish
38% bullish • 5 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MNKD shows positive signals but monitor for confirmation. Market pricing in 1.0% growth. Moderate conviction.
💡 BUY OPPORTUNITY: MNKD shows positive signals but monitor for confirmation. Market pricing in 1.0% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MNKD is currently trading at $6.00, which is considered extended relative to its 30-day fair value range of $5.52 to $5.86. The stock's valuation (Forward PE: 39.4) is in line with its historical norms (38.2). At these levels, the market is pricing in 1.0% annual earnings growth.
Technical Outlook: Technically, MNKD is in a uptrend. The price is approaching resistance at $6.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: MNKD has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.44 (+63.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MNKD is in a uptrend. The price is approaching resistance at $6.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.9% recently.
Market Sentiment: MNKD has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.44 (+63.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$5.52 -
$5.86
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.9%)
- BULLISH: Trading 63.3% below Wall St target ($9.44)
- BULLISH: Expecting earnings turnaround to 1.0% growth with 17.2% revenue growth
Fair Price Analysis
30-Day Fair Range
$5.52 -
$5.86
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$5.03
Resistance Level
$6.05
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
39.40
Wall Street Target
$9.44
(+63.3%)
Revenue Growth (YoY)
17.2%
Earnings Growth (YoY)
-34.9%
Profit Margin
9.3%
Valuation Premium vs History
+1.0% premium
PE vs Historical
39.4 vs 38.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.0%
(market-implied from PE analysis)
1-Year Target
$5.84
(+1%)
2-Year Target
$5.90
(+2%)
3-Year Target
$5.96
(+3%)
3-Yr Target (if PE normalizes)
(PE: 39→38)
PE COMPRESSION
$5.77
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 39.4, Growth: -24.1%)
$4.21
(+-27%)
Base:
(SPY PE: 22.3, Growth: -24.1%)
$2.38
(-59%)
Bear:
(PE: 19.0, Growth: -24.1%)
$2.03
(-65%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (51x PE), but valuation improves significantly next year (39x PE) as earnings recover.
Trailing PE: 50.70 | Current EPS (TTM): $0.10
Bull Case
$8.18
(+42%)
Analyst growth 46.7%, PE expands to 55.8
Base Case
$7.44
(+29%)
Market implied 46.7%, PE stable at 50.7
Bear Case
$3.45
(-40%)
Severe decline -20.0%, PE contracts to 43.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: February 02, 2026 2:42 PM ET
Data refreshes hourly during market hours. Next update: 3:42 PM
Data refreshes hourly during market hours. Next update: 3:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNKD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Stuart A Tross
SELL
47000 shares
2025-09-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
Advanced MNKD Option Strategies
Professional options setups generated by AI based on today's MNKD price and gamma walls.
